RT Journal Article
SR Electronic
T1 Rapid detection of neutralizing antibodies to SARS-CoV-2 variants in post-vaccination sera
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.06.21256788
DO 10.1101/2021.05.06.21256788
A1 Miyakawa, Kei
A1 Jeremiah, Sundararaj Stanleyraj
A1 Kato, Hideaki
A1 Yamaoka, Yutaro
A1 Go, Hirofumi
A1 Yamanaka, Takeharu
A1 Ryo, Akihide
YR 2021
UL http://medrxiv.org/content/early/2021/05/10/2021.05.06.21256788.abstract
AB The uncontrolled spread of the COVID-19 pandemic has led to the emergence of different SARS-CoV-2 variants across the globe. The ongoing global vaccination strategy to curtail the COVID-19 juggernaut, is threatened by the rapidly spreading Variants of Concern (VOC) and other regional mutants, which are less responsive to neutralization by infection or vaccine derived antibodies. We have previously developed the hiVNT system which detects SARS-CoV-2 neutralizing antibodies in sera in less than three hours. In this study, we modify the hiVNT for rapid qualitative screening of neutralizing antibodies (nAb) to multiple variants of concern (VOC) of SARS-CoV-2, and assess the neutralizing efficacy of the BNT162b2 mRNA vaccine on seven epidemiologically relevant SARS-CoV-2 variants. Here we show that the BNT162b2 mRNA vaccine can activate humoral immunity against the major SARS-CoV-2 mutants that are currently in circulation. Albeit a small sample size, we observed that one dose of vaccine was sufficient to elicit a protective humoral response in previously infected people. Using a panel of seven SARS-CoV-2 variants and a single prototype virus, our modified hiVNT would be useful for large-scale community wide testing to detect protective immunity that may confer vaccine/immune passport in the ongoing COVID-19 pandemic.Competing Interest StatementYY is a current employee of Kanto Chemical Co. Inc. The authors have no conflicts of interest directly relevant to the content of this article.Clinical TrialN/AFunding StatementThis study was supported by Rapid research and development Projects on COVID-19 of AMED (JP19fk0108110) to AR.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by Yokohama City University Certified Institutional Review Board (Reference No. B160800009, B200600115, B210300001), and the protocols used in the study were approved by the ethics committee.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets presented in this article are not readily available because it is difficult to ensure the de-identification of data. However, they can be available from the corresponding author on reasonable request. Requests to access the datasets should be directed to AR.